Mateon Therapeutics (MATN) Releases Quarterly Earnings Results, Meets Expectations

Mateon Therapeutics (OTCMKTS:MATN) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.02) EPS for the quarter, hitting the consensus estimate of ($0.02), MarketWatch Earnings reports.

Shares of MATN stock remained flat at $$0.20 during trading on Thursday. The stock had a trading volume of 11,934 shares, compared to its average volume of 69,073. Mateon Therapeutics has a 52 week low of $0.05 and a 52 week high of $0.31.

MATN has been the subject of several analyst reports. Zacks Investment Research raised Mateon Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, April 25th. HC Wainwright reissued a “hold” rating on shares of Mateon Therapeutics in a research note on Monday, April 22nd.

COPYRIGHT VIOLATION WARNING: This article was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.americanbankingnews.com/2019/05/16/mateon-therapeutics-matn-releases-quarterly-earnings-results-meets-expectations.html.

Mateon Therapeutics Company Profile

Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical, focuses on developing small molecule injectable drugs for the treatment of cancer. It is developing CA4P, an immuno-oncology agent that stimulates the immune system against the tumor; and OXi4503 for the treatment of relapsed/refractory acute myeloid leukemia.

Further Reading: How to track put option volume

Earnings History for Mateon Therapeutics (OTCMKTS:MATN)

Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply